Eye Care Physicians

Gain Early Insight on Macular Degeneration

Our AdaptDx™ measures dark adaptation function, which is severely impaired from the earliest stages of age-related macular degeneration (AMD), retinitis pigmentosa (RP), and other macular degenerations.

Learn More

Researchers

Advanced Dark Adaptometer
Expands Research Capabilities

The AdaptDx™ dark adaptometer provides researchers with a powerful new tool to study visual function and macular degenerative diseases.  

Learn More

Pharmaceutical Companies

Support for Next Generation
AMD Drug Development

Dark adaptation provides a more sensitive clinical endpoint in trials of drugs for age-related macular degeneration (AMD), retinitis pigmentosa (RP), and other macular degenerations.

Learn More

Patients

Early Detection of AMD
is Beneficial

Early detection allows early intervention to preserve vision and improve quality of life.

Learn More

Dark Adaptation
& Macular Degeneration

Age-related macular degeneration (AMD) is a progressive eye disease and a leading cause of blindness, affecting more than 9 million people in the U.S. alone. Retinitis pigmentosa (RP) and other macular degenerations affect hundreds of thousands more. These diseases impact an area of the retina called the macula where detailed central vision occurs. Numerous clinical studies have shown that dark adaptation—the recovery of vision when going from daylight to darkness—is dramatically impaired from the earliest stages of AMD, RP and other macular degenerations, with increasing impairment as the diseases progress.

Learn More

The AdaptDx® is the first instrument to provide a practical and objective measurement of dark adaptation function, which is severely impaired in AMD, RP, and other macular degenerations. It is a valuable complement to existing imaging devices used in routine eye exams for retinal disease assessment. This additional information is particularly valuable for early assessment, as biological function is often affected earlier than structural changes can be identified.

Learn More

Preserving Vision Before It's Too Late

Gregory R. Jackson, PhD, Associate Professor of Ophthalmology at Penn State College of Medicine, discusses the promise of the AdaptDx as a test for age-related macular degeneration (AMD), a disorder that affects millions of people, and often goes undiagnosed for years.

Watch Now